# Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

> **NCT07416409** · — · COMPLETED · sponsor: **Deraya University** · enrollment: 80 (actual)

## Conditions studied

- Breast Neoplasms
- Oncology
- HER2-positive Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab (Single-Agent Anti-HER2 Therapy)
- **DRUG:** Combination Anti-HER2 Therapy (Trastuzumab + Pertuzumab or Lapatinib)

## Key facts

- **NCT ID:** NCT07416409
- **Lead sponsor:** Deraya University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-10
- **Primary completion:** 2024-06-20
- **Final completion:** 2025-06-20
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416409, "Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07416409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*